Oculis (NASDAQ:OCS) Price Target Raised to $33.00 at Chardan Capital

Oculis (NASDAQ:OCS) had its price target raised by Chardan Capital from $28.00 to $33.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the stock.

OCS has been the subject of a number of other reports. Robert W. Baird lifted their price target on shares of Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a research report on Thursday, March 13th. HC Wainwright upped their target price on Oculis from $29.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, April 17th.

Oculis Stock Down 1.1 %

OCS opened at $18.49 on Friday. The business has a 50 day simple moving average of $18.03 and a 200-day simple moving average of $18.36. Oculis has a 12 month low of $10.79 and a 12 month high of $23.08. The stock has a market capitalization of $807.31 million, a P/E ratio of -9.58 and a beta of 0.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02.

Oculis (NASDAQ:OCS) last issued its earnings results on Wednesday, May 14th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.27). The company had revenue of $0.32 million for the quarter, compared to analysts’ expectations of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. On average, equities analysts anticipate that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Trading of Oculis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bellevue Group AG acquired a new position in Oculis in the fourth quarter valued at $170,000. Kestra Private Wealth Services LLC acquired a new position in shares of Oculis during the 1st quarter valued at about $234,000. XTX Topco Ltd purchased a new position in shares of Oculis during the 4th quarter worth about $225,000. Geode Capital Management LLC boosted its position in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after acquiring an additional 1,800 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in Oculis in the fourth quarter valued at approximately $389,000. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.